Francisco Javier Burgos Revilla-rekin lankidetzan egindako argitalpenak (5)

2023

  1. ProsTAV, a novel blood-based test for biopsy decision management in significant prostate cancer

    Prostate, Vol. 83, Núm. 14, pp. 1323-1331

2022

  1. Corrigendum to <‘Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center’> <[Volume 40, Issue 7, July 2022, Pages 345.e19-345.e23]> (Urologic Oncology: Seminars and Original Investigations (2022) 40(7) (345.e19–345.e23), (S1078143922000679), (10.1016/j.urolonc.2022.02.018))

    Urologic Oncology: Seminars and Original Investigations

  2. Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center

    Urologic Oncology: Seminars and Original Investigations, Vol. 40, Núm. 7, pp. 345.e19-345.e23

2017

  1. Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study – GESCAP group

    Actas Urologicas Espanolas, Vol. 41, Núm. 6, pp. 359-367

2016

  1. Tendencias de tratamiento en el cáncer de próstata clínicamente localizado. Análisis poblacional a nivel nacional: grupo GESCAP

    Actas Urologicas Espanolas, Vol. 40, Núm. 4, pp. 209-216